{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["25(2)"],"submitter":["Garcia J"],"pubmed_abstract":["<h4>Background and objectives</h4>The use of ultra-sensitive diagnostic tests to detect clinically actionable somatic alterations within the gene encoding the epidermal growth factor receptor (EGFR) within circulating cell-free DNA is an important first step in determining the eligibility of patients with non-small cell lung cancer to receive tyrosine kinase inhibitors.<h4>Methods</h4>We present the clinical validation (accuracy, sensitivity, and specificity) of a highly sensitive OncoBEAM<sup>TM</sup> EGFR V2 test, which we compare to a custom next-generation sequencing assay, for the treatment of patients with non-small cell lung cancer with EGFR tyrosine kinase inhibitor therapies. The OncoBEAM<sup>TM</sup> digital-polymerase chain reaction method detects 36 different EGFR alterations i"],"journal":["Molecular diagnosis & therapy"],"pagination":["239-250"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7956937"],"repository":["biostudies-literature"],"pubmed_title":["Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAM<sup>TM</sup> EGFR V2 and NGS Technologies."],"pmcid":["PMC7956937"],"pubmed_authors":["Couraud S","Duruisseau M","Payen L","Barthelemy D","Geiguer F","Gauthier A","Garcia J","Merle P","Balandier J","Jones FS","Holtrup F","Edelstein DL","Grolleau E","Lescuyer G","Rodriguez-Lafrasse C"],"additional_accession":[]},"is_claimable":false,"name":"Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAM<sup>TM</sup> EGFR V2 and NGS Technologies.","description":"<h4>Background and objectives</h4>The use of ultra-sensitive diagnostic tests to detect clinically actionable somatic alterations within the gene encoding the epidermal growth factor receptor (EGFR) within circulating cell-free DNA is an important first step in determining the eligibility of patients with non-small cell lung cancer to receive tyrosine kinase inhibitors.<h4>Methods</h4>We present the clinical validation (accuracy, sensitivity, and specificity) of a highly sensitive OncoBEAM<sup>TM</sup> EGFR V2 test, which we compare to a custom next-generation sequencing assay, for the treatment of patients with non-small cell lung cancer with EGFR tyrosine kinase inhibitor therapies. The OncoBEAM<sup>TM</sup> digital-polymerase chain reaction method detects 36 different EGFR alterations i","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2026-05-07T12:02:03.435Z","creation":"2022-02-09T08:14:40.384Z"},"accession":"S-EPMC7956937","cross_references":{"pubmed":["33660188"],"doi":["10.1007/s40291-021-00515-9"]}}